HemaCell has announced the completion of a Series B1 extension financing round worth tens of millions of RMB, coming just one week after closing the initial tranche of its Series B1 equity round. The investment, provided by the Hebei Hebei Coastal Industrial Investment Fund, will support the company's core technology for the ex vivo regeneration of platelet-lineage cells. This technology aims to address blood supply shortages, reduce the risk of transfusion-transmitted diseases and develop novel therapeutics derived from these regenerated platelets.

HemaCell's lead products, two megakaryocyte cell therapies, have already received investigational new drug (IND) approval in both its China homeland and the US. The company has also secured five orphan drug designations (ODD) and two rare paediatric disease designations (RPDD) from US regulators for its platelet-based candidates. With several INDs expected in 2026, the company plans to use the new capital to accelerate product development and initiate overseas expansion efforts.

According to PharmCube's MedAlpha® database, HemaCell has raised over USD 43 million in funding since 2021. Click here to request a free trial for MedAlpha®.